CSL Shares Continue Lower as Update Adds Fuel To Bear Case: The Latest

CSL shares (ASX: CSL) continue to fight against bearish momentum, with today’s index worst 15.77% drop to close at A$100.97 coming after the biopharmaceutical giant slashed earnings guidance and flagged approximately $5 billion in additional asset write-downs tied largely to its troubled Vifor acquisition.

Sentiment had already been negative leading in to the update, and the move on the day was dramatic, as CSL share price hit an intraday low of A$93.64, the weakest level in a decade, before mounting a modest recovery attempt to claw back above the psychologically important A$100 mark.

CSL ended the session as the worst performer on the S&P/ASX 200 index, extending its year-to-date decline to a brutal 41.34%. With a Relative Strength Index now sitting at just 11.44, CSL has become the most oversold stock on the Australian Securities Exchange, a technical signal that typically indicates extreme selling pressure and potential capitulation by long-term holders. Whilst technical traders will use oversold signals as part of a potential reversal trade, the fundamental backdrop at CSL is giving precious little indication that momentum is set to change soon.

What Happened to CSL Today?

The trigger for today’s collapse was a 90-day interim CEO review and financial update that delivered a triple blow: downgraded earnings guidance, a massive impairment charge, and confirmation that multiple headwinds will weigh on near-term performance.

CSL now expects FY26 revenue of approximately US$15.2 billion on a constant currency basis, with net profit after tax and amortisation (NPATA) forecast at around US$3.1 billion. Both figures represent meaningful downgrades from earlier market expectations and extend a pattern of guidance reductions that has plagued the company over the past year.

The company also flagged additional non-cash, pre-tax asset impairments of roughly US$5 billion to be recognised across FY26 and FY27. The bulk of these write-downs relate to CSL Vifor intangibles as well as under-utilised manufacturing assets, including some within the Seqirus vaccines division. These new charges come on top of approximately US$1.1 billion in after-tax impairments already booked in the first half of FY26, bringing the total write-down tally to around US$6 billion and raising serious questions about the Vifor deal’s strategic rationale and execution.

Management detailed three specific revenue headwinds that explain the guidance cut. US Immunoglobulin revenue is expected to take a US$300 million hit due to inventory normalisation, as distributors and hospital systems work through excess stock built up during earlier supply-chain disruptions. Albumin sales in China will decline by approximately US$200 million despite volume and market-share gains, as government-mandated price cuts and broader market deflation more than offset physical demand growth. An additional US$150 million revenue drag will come from a combination of Middle East conflict disruptions, increased product competition, and other macroeconomic pressures.

The impairments are particularly damaging to management credibility. The Vifor acquisition was positioned as a strategic diversification play that would reduce CSL’s reliance on plasma-derived therapies and add high-growth nephrology and iron-deficiency franchises. Instead, the legacy iron portfolio has significantly underperformed initial projections, forcing management to admit that the acquisition’s expected cash flows and returns on invested capital will not materialise as planned.

Positioning From Here

Despite the grim headline numbers, CSL emphasised that its core plasma collection and influenza vaccine businesses remain structurally sound. The company highlighted ongoing demand growth in key immunoglobulin and albumin markets, with plasma collection volumes continuing to expand and the global installed base of collection centres providing a durable competitive moat. Management noted that while pricing pressure and short-term inventory dynamics are weighing on revenue, underlying patient demand for critical-care therapies remains robust.

CSL Seqirus, the company’s vaccines division, is tracking moderately ahead of earlier forecasts for FY26 and is expected to outperform previous guidance. The division has benefited from strong flu vaccine demand and ongoing investments in next-generation cell-based manufacturing platforms that promise improved margins and scalability over time.

The company is also pushing forward with a large-scale transformation and efficiency program targeting A$500 million to A$550 million in annual cost savings by FY28. The initiative focuses on simplifying the organisational structure, eliminating duplication across the enlarged post-Vifor business, and concentrating capital expenditure on the highest-return growth opportunities. Management believes these structural cost reductions will help restore margin expansion and support mid-to-high single-digit earnings growth once the current reset period is complete.

CSL expects to see revenue growth resume in its CSL Behring plasma division during the second half of FY26, underpinned by improved commercial execution, the benefits of transformation initiatives, and the gradual normalisation of US immunoglobulin inventory levels. A further comprehensive update will be provided alongside the company’s full-year results in August 2026.

Outlook

From a valuation perspective, CSL now trades at a significant discount to its long-term historical average price-to-earnings multiple, reflecting the market’s loss of confidence in the company’s growth trajectory and return on capital. Bulls would argue that the extreme technical oversold condition, with the RSI at just 11.44, suggests panic selling has pushed the stock well below fair value, creating a rare opportunity to accumulate a world-class franchise at a multi-year low.

Bears counter that CSL is transitioning from a high-growth compounder to a mature, slower-growth healthcare utility, and that even at current levels the stock may not be cheap if earnings growth remains stuck in the low-to-mid single digits. They highlight ongoing risks from Chinese pricing pressure, potential demand headwinds from new therapies such as GLP-1 weight-loss drugs, and the possibility of further negative surprises as the interim CEO review continues to uncover operational issues.

The next major fundamental update is expected in August, but it could be a bumpy ride before then for anyone still holding CSL.